Rigel Pharmaceuticals, Inc.
- RIGL
- NASDAQ
- Biotechnology
- Hematology/Oncology Biotech
- SYK Inhibitor (TAVALISSE)
$47.01
Today +2.26%Quote Oct 19, 2026, 05:00 PM UTC
+0.26%over the last month
Max drawdown −6.9%From 1-month high −6.9%3 months +15.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Where the money comes from
Q2 2026 revenue $171.2M
- Gross Product$88.5M51.7%
- Product$67.0M39.2%
- Contract revenues from collaborations$11.7M6.8%
- Development Milestones$4.0M2.3%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
173
Founded
1996
Market value
$878.1M
Quote Oct 19
Floor
$46.04
2.1% below price
Resistance
$47.12
0.2% above price
Price vs analyst targets
15 analysts
Lowest target
$49.00Highest target
$85.00
$49.00Highest target
$85.00
- Price $47.01
- Average target $67.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 43% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RIGLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free